GlaxoSmithKline Will Move Priority Neurological Drug Research From China to US
Chen Juan
/SOURCE : Yicai
GlaxoSmithKline Will Move Priority Neurological Drug Research From China to US

(Yicai Global) Aug. 3 -- International pharmaceutical giant GlaxoSmithKline plc [LON:GSK] (GSK), said that as part of its focused research and development strategy, it will narrow the scope of its neuroscience R&D activities and terminate some undertakings.

The priority projects for the R&D of nervous system drugs in Shanghai will continue and be transferred to the firm's center in Upper Providence Township, Pennsylvania in the US.

GSK said the transition will ensure that the company can continue to work on key initiatives and integrate them with the future drug R&D team.

In the next two years, the size of the company's drug development team in Shanghai Zhangjiang Hi-Tech Park will continue to expand to promote the creation of new drugs in China. GSK's cervical cancer vaccine was officially introduced to the market this week. It is the first cervical cancer vaccine approved in the country. Some institutions had previously predicted that the market scale of the vaccine could reach USD14.9 billion (CNY100 billion).

Follow Yicai Global on
Keywords: GSK , RESEARCH , Zhangjiang High-Tech Park